Irwin Lucki Ph.D.

Education

Education: 1972 B.A. University of Illinois, Psychology
1976 M.A. University of Iowa, Psychology
1979 Ph.D. University of Iowa, Biopsychology
Postgraduate Training:
1979-1981 Postdoctoral Research Fellow, Psychopharmacology Training Program, Department of Psychiatry, University of Pennsylvania

Biography

Selected from 180 publications:
Cryan, J.F., Valentino, R.J. and Lucki, I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neuroscience and Biobehavioral Reviews, 2005, 29:547-569.
Valentino, R.J., Lucki, I. and Van Bockstaele, E. Corticotropin-releasing factor in the dorsal raphe nucleus: Linking stress coping and addiction. Brain Research, 2010, 1314:29-37. PMC2819581
Ho, N., Sommers, M.S. and Lucki, I. Effects of diabetes on hippocampal neurogenesis: Links to cognition and depression. Neuroscience and Biobehavioral Reviews, 2013, 37:1346-1362. PMC3788092
Browne, C.A. and Lucki, I. Mechanisms mediating the antidepressant-like Lucki, I. The spectrum of behaviors influenced by serotonin. Biological Psychiatry, 1998, 44:151-162.
Page, M.E., Cryan, J.F., Sullivan, A., Dalvi, A. and Lucki, I. Behavioral and neurochemical effects of EMD 68843: A combined selective inhibitor of serotonin reuptake and partial 5-HT1A receptor agonist. Journal of Pharmacology and Experimental Therapeutics, 2002, 302:1-8.
Carr, G.V. and Lucki, I. The role of serotonin receptor subtypes in treating depression: A review of animal studies. Psychopharmacology, 2011, 213:265-287. PMC3374933
Carr, G.V., Schechter, L.E. and Lucki, I. Antidepressant and anxiolytic effects of
selective 5-HT6 receptor agonists in rats. Psychopharmacology, 2011, 213:499-507. PMC2910165
effects of ketamine: Screening for fast-acting novel antidepressants. Frontiers in Neuropharmacology, 2013, 4:161, 1-18. PMC3873522.
Mayorga, A.J., Dalvi, A., Page, M.E., Zimov-Levinson, S., Hen R. and Lucki, I. Antidepressant-like behavioral effects in 5-HT1A and 5-HT1B receptor mutant mice. Journal of Pharmacology and Experimental Therapeutics, 2001, 298:1101-1107.
Cryan, J.F., O’Leary, O.F., Jin, S.-H., Friedland, J.C., Ouyang, M., Hirsch, B.R., Page, M.E., Dalvi, A., Thomas, S.A. and Lucki, I. Norepinephrine deficient mice lack responses to antidepressant drugs, including SSRIs. Proceedings of the National Academy of Sciences, 2004, 101:8186-8191.
O’Leary, O.F., Bechtholt, A.J., Crowley, J.J., Valentino, R.J. and Lucki, I. The role of noradrenergic tone in the dorsal raphe nucleus of the mouse in the acute behavioral effects of antidepressant drugs. European Neuropsychopharmacology, 2007, 17:215-226.
Balu, D.T., Turner, J.R., Brookshire, B.R., Hill, T.E., Blendy, J.A. and Lucki, I. Brain monoamines and responses to antidepressant drugs in MRL/MpJ versus C57BL/6J and mice. Neuropharmacology, 2013, 67:503-510. PMC437180
Cryan, J.F., Markou, A. and Lucki, I. Assessing antidepressant-like activity in laboratory animals: Recent developments and future needs. Trends in Pharmacological Sciences, 2002, 23(5): 238-245.
Crowley, J.J. and Lucki, I. Opportunities to discover genes regulating depression and antidepressant response from rodent behavioral genetics. Current Pharmaceutical Design, 11:157-169, 2005.
Bechtholt, A.J., Valentino, R.J. and Lucki, I. Overlapping and distinct brain regions associated
with the anxiolytic effects of chlordiazepoxide and chronic fluoxetine. Neuropsychopharmacology, 2008, 33:2117-2130.
Carr, G.V., Bangasser, D.A., Bethea, T., Young, M., Valentino, R.J. and Lucki, I. Antidepressant-like effects of kappa opioid receptor antagonists in Wistar-Kyoto rats. Neuropsychopharmacology, 2010, 35(3):752-63. PMC2813986
Price, M. L., Curtis, A.L., Kirby, L.G., Valentino, R.J. and Lucki, I. Biphasic effects of corticotropin-releasing factor on brain serotonergic activity. Neuropsychopharmacology, 1998, 18:492-502.
Price, M.L. and Lucki, I. Regulation of serotonin release in the lateral septum and striatum by corticotropin-releasing factor. Journal of Neuroscience, 2001, 21:2833-2841.
Howard, O., Carr, G.V., Hill, T.E., Valentino, R.J. and Lucki, I. Differential blockade of CRF-evoked behaviors by depletion of norepinephrine and serotonin. Psychopharmacology, 2008, 199:569-82. PMC2744742
Snyder, K.P., Hill-Smith, T.E., Lucki, I. and Valentino, R.J. Corticotropin-releasing factor in the rat dorsal raphe nucleus promotes different forms of behavioral flexibility depending on social stress history. Neuropsychopharmacology, 2015, 40:2517-25. PMCID in process.
Carr, G.V., Bangasser, D.A., Bethea, T., Young, M., Valentino, R.J. and Lucki, I. Antidepressant-like effects of kappa opioid receptor antagonists in Wistar-Kyoto rats. Neuropsychopharmacology, 2010, 35(3):752-63. PMC2813986
Falcon, E., Maier, K., Robinson, S.A. and Lucki, I. Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice. Psychopharmacology, 2015, 232:907-915. PMC4326609
Browne, C.A., van Nest, D. and Lucki, I. Antidepressant-like effects of buprenorphine in rats are strain dependent. Behavioural Brain Research, 2015, 278:385-392. PMC4382376
Falcon, E., Browne, C.A., Leon, R.M., Fleites, V.C., Sweeney, R., Kirby, L.G. and Lucki, I. Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors. Neuropsychopharmacology, 2016, 41(9):2344-2351. PMC4946065
A full bibliography of over 170 peer-reviewed publications is available at: http://www.ncbi.nlm.nih.gov/sites/myncbi/irwin.lucki.1/bibliography/45296221/public/?sort=date&direction=ascending.

Career Highlights: Positions, Projects, Deployements, Awards and Additional Publications

2007 - present, Principal Field Editor, Psychopharmacology

1995 - present, Editorial Advisory Board, Neuropsychopharmacology

2014 – present, Editorial Advisory Board, Neurobiology of Stress

Buprenorphine for Depression and Anxiety.PI. NIMH, R01 MH92412, 2012-2018. Total direct costs = $1,250,000. The goal of this grant is to examine animal models supporting the development of buprenorphine for the clinical treatment of depression and anxiety.

Kappa Receptor Antagonists as Rapid Acting Antidepressants. PI. NIMH, R01 MH105623, 2016-2020. Total direct costs = $1,000,000. The goal of this grant is to study animal models supporting the development of novel kappa receptor antagonists for the clinical treatment of mood disorders.

Training Program in Neuropsychopharmacology. NIMH, T32 MH14654-34-38, 1978-2021. I was Training Program Director at the University of Pennsylvania 1992-2016.

Regulation of Hippocampal Neurogenesis by Antidepressants. PI. NIMH, R01 MH86599, 2009-2015.

Biology of Serotonin in Brain; Program Project Grant: Irwin Lucki, Ph.D., Program Director (1994-2007). NIMH, PO1-MH-48125.

Regulation of Neurogenesis by Stress and Antidepressants. Program Director. National Cooperative Drug Discovery Group involving University of Pennsylvania and Wyeth Neuroscience. U01-MH 72832, 2005-2009.

Representative Bibliography

2016- present Professor (with tenure) and Chair, Department of Pharmacology and Molecular Therapeutics, Uniformed University of the Health Sciences, Bethesda MD

2016-present Professor, Department of Psychiatry, Uniformed University of the Health Sciences, Bethesda MD

1996-2016 Professor of Psychology in Psychiatry (with tenure), Depts. of Psychiatry and Pharmacology, University of Pennsylvania, Philadelphia PA

1990-1996 Associate Professor of Psychology in Psychiatry (with tenure), Depts. of Psychiatry and Pharmacology, University of Pennsylvania, Philadelphia PA

1989-1990 Assistant Professor, Department of Pharmacology, University of Pennsylvania, Philadelphia PA

1984-1990 Assistant Professor of Psychology in Psychiatry, Department of Psychiatry, University of Pennsylvania, Philadelphia PA

1981-1984 Research Associate, Department of Psychiatry, University of Pennsylvania, Philadelphia PA